Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Biocryst Pharmaceuticals Inc (BCRX)

299 + Investors. Track Smart Money conviction in BCRX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +27
Streak
1Q ▲
Buyers last Q
61%

Smart Money Signals — BCRX

Based on 300 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added BCRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
300 hedge funds hold BCRX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +10% more funds vs a year ago

fund count last 6Q
+28 new funds entered over the past year (+10% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟢

More buyers than sellers — 61% buying

191 buying123 selling
Last quarter: 191 funds were net buyers (73 opened a brand new position + 118 added to an existing one). Only 123 were sellers (77 trimmed + 46 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+22 vs last Q)

new funds entering per quarter
Funds opening a new BCRX position: 54 → 38 → 51 → 73. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

55% of holders stayed for 2+ years

■ 55% conviction (2yr+) ■ 22% medium ■ 23% new
164 out of 300 hedge funds have held BCRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +43% but shares only +20% — price-driven

Value
+43%
Shares
+19%
Last quarter: the total dollar value of institutional holdings rose +43%, but actual share count only changed +20%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📈

Growing discovery — still being found

46 → 54 → 38 → 51 → 73 new funds/Q
New funds entering each quarter: 54 → 38 → 51 → 73. A growing number of institutions are discovering BCRX each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 64% veterans vs 26% newcomers

■ 64% veterans ■ 10% 1-2yr ■ 26% new
Entry-cohort mix of 312 holders: 201 (64%) are 2+ year veterans, 30 entered 1–2 years ago, and 81 (26%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 37% AUM from major funds

37% from top-100 AUM funds
52 of 298 holders rank in the top 100 by AUM, accounting for 37% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.6
out of 10
Low Exit Risk
Exit risk score 3.6/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — BCRX

In 2026 Q1, 191 hedge funds were net buyers of BCRX (73 opened a new position, 118 added to an existing one), while 123 reduced or exited (77 trimmed, 46 sold completely) — a 61% buyer ratio, indicating clear institutional accumulation. 37% of total institutional value in BCRX is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +27 funds (more new holders than closures). Total institutional holders: 300.

Hedge Fund Ownership: BCRX

How many hedge funds hold BCRX — quarterly history vs. share price
Quarterly hedge fund ownership of BCRX vs. share price

Market Analysis: BCRX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: BCRX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Biocryst Pharmaceuticals Inc (BCRX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much BCRX has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 47d ago
BCRX
-2.6%
XLV
+5.5%

BCRX outperformed XLV by -8.1% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 2d ago
BCRX
+0.0%
XLV
+0.0%

Since the filing became public, BCRX outperformed XLV by +0.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

27 top-rated funds 6 high-conviction
Consensus
6.3
/ 10
breadth
×
Elite
3.3
/ 10
conviction
Hedge Fund Positioning: BCRX
2026 Q2 Stats Unlock in 3 days 299 + Investors

Track Smart Money conviction in BCRX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 299 272 9.93%
13F Shares 252M 210M 19.75%
Total Value $2.35B $1.64B 43.28%
New Positions 72 50 +22
Increased Positions 115 90 +25
Closed Positions 45 62 -17
Reduced Positions 75 100 -25
Total Calls 8 8 -
Total Puts 6 9 -33.33%
PUT/CALL Ratio 0.75 1.12 Neutral

Statistics: BCRX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

299 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in BCRX. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 BCRX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Rosalind Advisors, Inc. 2.68% 721,504 $7.2M
2 TCG Crossover Management, LLC 2.65% 11,020,968 $110.2M
3 Vestal Point Capital, LP 1.94% 8,300,000 $83.0M
4 Cannon Global Investment Management, LLC 1.69% 59,700 $597K
5 Parkman Healthcare Partners LLC 1.66% 1,624,279 $16.2M
6 Deerfield Management Company, L.P. 1.57% 15,096,403 $151.0M
7 Perceptive Advisors LLC 1.55% 10,308,888 $103.1M
8 Kynam Capital Management, LP 1.39% 2,522,660 $25.2M
9 Ra Capital Management, L.P. 1.38% 15,827,186 $158.3M
10 Elmind Capital, LP 1.31% 520,000 $5.2M
11 Rice Hall James & Associates, LLC 1.13% 2,332,043 $23.3M
12 Eversept Partners, LP 0.97% 1,865,653 $18.7M
13 Frazier Life Sciences Management, L.P. 0.87% 4,009,240 $40.1M
14 Doliver Advisors, LP 0.85% 374,328 $3.7M
15 DAFNA Capital Management LLC 0.76% 400,248 $4.0M
16 Nantahala Capital Management, LLC 0.63% 1,901,160 $19.0M
17 QTR Family Wealth, LLC 0.56% 161,082 $1.6M
18 Sphera Funds Management LTD. 0.55% 422,051 $4.2M
19 Hussman Strategic Advisors, INC. 0.48% 210,000 $2.1M
20 Phocas Financial Corp. 0.47% 340,541 $3.4M
21 NAN FUNG TRINITY (HK) Ltd 0.44% 450,000 $4.5M
22 Marble Bar Asset Management LLP 0.43% 62,339 $623K
23 Orbimed Advisors LLC 0.34% 1,852,000 $18.5M
24 Virtus Investment Advisers, LLC 0.31% 133,664 $1.3M
25 Counterweight Ventures, LLC 0.31% 62,050 $620K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Biocryst Pharmaceuticals Inc (BCRX)

What does the Smart Money Trend signal show for BCRX?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added BCRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for BCRX?

More buyers than sellers — 61% buying: Last quarter: 191 funds were net buyers (73 opened a brand new position + 118 added to an existing one). Only 123 were sellers (77 trimmed + 46 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for BCRX holders?

Strong quality — 37% AUM from major funds: 52 of 298 holders rank in the top 100 by AUM, accounting for 37% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held BCRX?

55% of holders stayed for 2+ years: 164 out of 300 hedge funds have held BCRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Biocryst Pharmaceuticals Inc (BCRX) following the 2026 Q2 hedge fund 13F filings?

As of today, BCRX has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), BCRX has gained -2.6% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →